A famend professional in insulin pharmacology, diabetes expertise, and temperature-sensitive medicine stability joins TempraMed to strengthen scientific management
Vancouver, British Columbia–(Newsfile Corp. – December 10, 2025) – TempraMed Technologies Ltd. 
VIVI (“TempraMed” or the “Company“), a medical expertise innovator remodeling how temperature-sensitive medicines are saved and managed, as we speak introduced the appointment of Professor Dr. Lutz Heinemann, one of many world’s foremost diabetes researchers, to its Scientific Advisory Board. His appointment additional enhances TempraMed’s scientific basis because the Company expands its portfolio of next-generation thermal-stability applied sciences for temperature-sensitive medicines.
Prof. Heinemann is internationally acknowledged for pioneering work that bridges insulin pharmacology, diabetes expertise, and drug-stability science. As co-founder of the Profil Institute for Metabolic Research and former Managing Editor of the Journal of Diabetes Science and Technology, he has performed a central function in advancing insulin kinetics, steady glucose monitoring (CGM), synthetic pancreas methods, and the scientific translation of recent diabetes applied sciences.
Beyond system innovation, Prof. Heinemann has revealed foundational analysis demonstrating the crucial impression of temperature on insulin and different peptide-based medicines, highlighting how improper storage outdoors the chilly chain can degrade efficiency, cut back therapeutic effectiveness, and compromise affected person security. His twin expertise-deep scientific understanding paired with real-world medication-handling insights-positions him as a worldwide authority on the scientific implications of thermal instability.
“As a researcher who has spent decades investigating how temperature fluctuations impact the stability and safety of insulin and other injectable medications, I have seen firsthand how real-world storage conditions can jeopardize treatment outcomes. TempraMed’s technologies offer a scientifically sound and practical solution to this long-standing challenge. I am pleased to join the advisory board and support their mission to improve medication safety and reliability for patients around the world,” commented Prof. Dr. Lutz Heinemann.
Ron Nagar, CEO, TempraMed, stated: “We are privileged to welcome Prof. Heinemann to TempraMed’s Scientific Advisory Board. His contributions to diabetes research have shaped global understanding of insulin behavior, technology innovation, and medication stability. Having his guidance is invaluable as we continue developing solutions that improve the daily lives of people managing chronic diseases by ensuring their medications remain safe, effective, and reliable-wherever life takes them. We look forward to working with Prof Heinemann, as his guidance and advice will be invaluable as we continue to advance our global offering.”
Strategic Significance for TempraMed
Prof. Heinemann’s intensive background enhances TempraMed’s capabilities throughout a number of high-priority domains:
- Global partnerships: Strengthening TempraMed’s engagement with potential companions; pharma, payors, scientific networks, digital-health platforms, and diabetes-technology leaders to drive collaborative innovation, scale distribution, and assist broad market adoption.
- Market entry and schooling: Helping form medical-professional and patient-facing steerage about temperature-sensitive medicine dealing with.
- Clinical validation and proof era: Supporting TempraMed’s scientific research on medicine stability, adherence, and clinical-use instances.
- Technology analysis: Providing professional perception into system performance, efficiency necessities, and integration with digital-health ecosystems.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a worldwide chief in modern, temperature-controlled medicine storage options. Founded with the mission to safeguard the effectiveness of life-saving medicines, TempraMed develops patented, FDA-registered, space-grade thermal insulation units that work 24/7 with out batteries or exterior energy. With a confirmed product line together with VIVI Cap and VIVI Epi, and a wise expertise platform on the horizon, TempraMed allows sufferers and healthcare suppliers to confidently handle temperature-sensitive medicines anyplace, anytime. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed is advancing the way forward for medicine safety and adherence.
Investors studying extra about TempraMed are inspired to contact the Company at:
www.tempramed.com
Contact:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
Media
Brenda Zeitlin
Vice President, Marketing
Cautionary Statements
This press launch comprises “forward-looking statements or information.” Forward-looking statements will be recognized by phrases similar to: anticipate, intend, plan, aim, search, consider, venture, estimate, anticipate, technique, future, probably, could, ought to, will and comparable references to future intervals. Examples of forward-looking statements on this press launch embrace statements made relating to details about future plans, expectations and goals of the Company total.
Forward-looking statements are neither historic information nor assurances of future efficiency. Instead, they’re based mostly solely on our present beliefs, expectations and assumptions relating to the way forward for our enterprise, future plans and techniques, projections, anticipated occasions and tendencies, the economic system and different future situations. Because forward-looking statements relate to the longer term, they’re topic to inherent uncertainties, dangers and modifications in circumstances which might be tough to predict and lots of of that are outdoors of our management. Our precise outcomes and monetary situation could differ materially from these indicated within the forward-looking statements. Therefore, you shouldn’t depend on any of those forward-looking statements. The Company could not truly obtain its plans, projections, or expectations. The forward-looking statements and knowledge are based mostly on sure key expectations and assumptions made by the Company. Important elements that would trigger our precise outcomes and monetary situation to differ materially from these indicated within the forward-looking statements embrace, amongst others, the next: the adequacy of our money circulation and earnings, the supply of future financing and/or credit score, developments and modifications in legal guidelines and laws, shopper sentiment in the direction of the Company’s merchandise, failure of counterparties to carry out their contractual obligations, authorities laws, competitors, lack of key workers and consultants, and basic financial, market or enterprise situations, the impression of expertise and social modifications on the merchandise and trade.
Any forward-looking assertion made by us on this press launch is predicated solely on info at the moment accessible to us and speaks solely as of the date on which it’s made. Except as required by relevant securities legal guidelines, we undertake no obligation to publicly replace any forward-looking assertion, whether or not written or oral, that could be constructed from time to time, whether or not on account of new info, future developments or in any other case.
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/launch/277598